DecisionRx, Inc., a company specializing in Medication Therapy Optimization (MTO), and BeneCard PBF, a Pharmacy Benefit Facilitator (PBF), have announced a strategic partnership. This collaboration aims to provide personalized, data-driven medication insights to BeneCard PBF’s clients and members across the United States, with goals to reduce medication failure, improve health outcomes, and generate measurable savings for employers and health plans.The partnership integrates DecisionRx, Inc.’s advanced pharmacogenomics and analytics platform with BeneCard PBF’s transparent, outcomes-focused PBF model. DecisionRx, Inc.’s MTO solution employs clinical pharmacists, genomic data, and prescription intelligence to ensure therapies are effective, personalized, and safe, addressing the estimated 40% of prescriptions that may be ineffective or harmful.BeneCard PBF operates with a pass-through, auditable pricing model and a member-first philosophy, which aligns with DecisionRx, Inc.’s value-based, evidence-driven clinical approach. Both organizations will offer value-based and risk-share options for plan sponsors, designed to link financial incentives directly to measurable improvements in health outcomes and cost savings.Jeff Shea, President of BeneCard PBF, stated, “At BeneCard PBF, we’ve believed in the power of pharmacogenomics from the beginning. This partnership elevates our capabilities, shifting the focus from mere testing to real-time, evidence-based action. As a Pharmacy Benefit Facilitator, our role is to facilitate better health outcomes, and with this evolved value-based approach tied to results, we are proud to offer our clients and their members the evidence-based care they deserve.”Travis Morgan, Co-Founder and President of DecisionRx, added, “We are excited by the opportunity to impact the lives of BeneCard PBF’s members through our MTO platform. Innovative PBM partners like BeneCard understand that medication therapy optimization is more than cost management—it’s about empowering better clinical decision-making and improving patient outcomes.”The collaboration is intended to provide several advantages for clients and members. Providers and patients will receive custom medication guidance informed by genomic and claims data, aiming to improve therapeutic accuracy and reduce trial-and-error prescribing. Studies indicate that DecisionRx’s MTO model can reduce annual total cost of care by approximately $3,600 per Medicare patient and around $1,200 for enrollees under 65. Furthermore, BeneCard PBF’s fully auditable, pass-through PBF model aims to ensure clients have full transparency regarding financial expenditures, while DecisionRx’s outcome-oriented clinical services offer a compelling value proposition to union health funds, self-insured employers, and other plan sponsors.BeneCard PBF describes itself as a pharmacy benefit facilitator committed to redefining pharmacy benefits through a transparent, member-centered approach. It partners with employers, labor funds, and health plans to deliver clear pricing, flexible programs, and improved health outcomes. DecisionRx is identified as a value-based healthcare company focused on reducing medication failure and healthcare waste using its patented Medication Therapy Optimization platform. The company’s clinical pharmacists use data science and clinical evidence to deliver personalized medication recommendations, which has been shown to reduce total annualized healthcare costs by avoiding unnecessary outpatient, inpatient, and emergency department utilization.